These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15529592)
61. [Aldosterone in patients with chronic circulatory insufficiency]. KODEJSZKO E; KOLINSKA M; KUCZEWSKA K; TATON J Pol Tyg Lek (Wars); 1959 Feb; 14(5):193-6. PubMed ID: 13667539 [No Abstract] [Full Text] [Related]
62. Renal and extrarenal actions of aldosterone. GROSS F Experientia; 1961 Feb; 17():57-64. PubMed ID: 13709009 [No Abstract] [Full Text] [Related]
63. [Clinical and biological efficacy of a spirolactone in the treatment of various water-salt retentions]. WAREMBOURG H; LINQUETTE M; LEKIEFFRE J; FOSSATI P Lille Med; 1961; 6():668-71. PubMed ID: 14004979 [No Abstract] [Full Text] [Related]
64. ALDOSTERONE antagonists as antihypertensive agents. Am J Cardiol; 1958 Dec; 2(6):775. PubMed ID: 13594865 [No Abstract] [Full Text] [Related]
66. Glomerulotropic activity of an acetone extract of pineal tissue. FARRELL G Endocrinology; 1959 Aug; 65(2):239-41. PubMed ID: 13672146 [No Abstract] [Full Text] [Related]
67. Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases. Matarese G; Norata GD Cardiovasc Res; 2020 Feb; 116(2):256-257. PubMed ID: 31346597 [No Abstract] [Full Text] [Related]
68. Comment on: AGS And NIA bench-to bedside conference summary: Cancer and cardiovascular disease. Lisi DM J Am Geriatr Soc; 2023 May; 71(5):1670-1675. PubMed ID: 36929848 [No Abstract] [Full Text] [Related]
69. Exercise and Pharmacology as Medicine for Cardiovascular Diseases: From Bench to Bedside and Back. Bruns DR; Walker LA Exerc Sport Sci Rev; 2018 Jan; 46(1):2-3. PubMed ID: 28902725 [No Abstract] [Full Text] [Related]
70. The importance of aldosterone in clinical medicine. NELSON DH Med Clin North Am; 1958 Sep; 42(5):1195-204. PubMed ID: 13599741 [No Abstract] [Full Text] [Related]
72. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
73. Aldosterone and cardiovascular pathology: from bench to bedside. Vintilă M; Băluţă M Rom J Intern Med; 2004; 42(1):15-26. PubMed ID: 15529592 [TBL] [Abstract][Full Text] [Related]
74. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies. Pasquale PD; Stefano GD; Paterna S Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838 [TBL] [Abstract][Full Text] [Related]
76. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Dieterich HA; Wendt C; Saborowski F Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159 [TBL] [Abstract][Full Text] [Related]